pulmoПульмонологияPULMONOLOGIYA0869-01892541-9617Scientific and Practical Journal “PULMONOLOGIYA” LLCpulmo-3465Research ArticleНОВОЕ О ЛЕКАРСТВЕННЫХ ПРЕПАРАТАХКлинические аспекты применения макролидных антибиотиковClinical aspects of the use of macrolide antibioticsЙерманАленкаJermanAlenkaДриновецЙожеDrinovetsJozhe199630091996039094Copyright © Йерман А., Дриновец Й., 19961996Йерман А., Дриновец Й.Jerman A., Drinovets J.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.pulmonology.ru/pulm/article/view/3465

Благодаря доказанной эффективности макролидных антибиотиков против внутриклеточных возбудителей инфекции и микроорганизма Helicobacter pylori, а также появлению новых макролидных антибиотиков (мидекамицина, кларитромицина, азитромицина, рокситромицина), увеличился интерес к ним и восстановилось их значение. Макролиды представляют собой эффективную замену пенициллинам у больных с аллергией к ним. Важным свойством макролидов является отличное проникновение в ткани и жидкости организма. После реабсорбции они выделяются в основном через печень, поэтому необходимости в снижении доз вследствие уменьшения функции почек нет. Новейшие макролиды обладают, в сравнении с эритромицином, более выгодной фармакокинетикой и вызывают меньше побочных явлений. В ближайшем будущем можно ожидать, наряду с появлением новых макролидов, также подтверждение их эффективности при различных клинических состояниях и различных возбудителях.

The conclusive evidence in support of the efficacy of macrolide antibiotics against introcellular infection causing pathogens and Helicobacter pylori on one side and the development of new macrolide antibiotics (midecamycin, clarithromycin, azithromycin, roxithromycin) on the other reversed the increased interest in this group of antibiotics and revived their popularity. Macrolides present an effective alternative to penicillins in patients with allergy to penicillin, hey are characterized by an exellent tissue and body fluids penetration. Following reabsorption, their main route of excretion is trough the liver, therefore no reduction in dosage is required in patients with impaired renal function. Compared with erythromycin, the newer macrolides possess a more favorable pharmacokinetic profile and are associated with less side effects. In the near future, not only further development of new forms of macrolide antibiotics may be expected but also a proof of their efficacy against varios pathogens in a range of clinical conditions.

ReferencesPeriti P., Mazzei Т., Mini E. Novelli A. Adverse effects of macrolide antibacterials // Drug Safety. — 1993. — Vol. 9. — P. 346—364.Periti P., Mazzei Т., Mini E. Novelli A. Adverse effects of macrolide antibacterials // Drug Safety. — 1993. — Vol. 9. — P. 346—364.Bryskier A., Agour idas C., Chantot J.F. Structure and activity // Neu H.C., Young L.S. Zinner S.H. Eds. The New Macrolides, Azalides, and Streptogramins. New York: Marcel Dekker, 1993. — P. 3—11.Bryskier A., Agour idas C., Chantot J.F. Structure and activity // Neu H.C., Young L.S. Zinner S.H. Eds. The New Macrolides, Azalides, and Streptogramins. New York: Marcel Dekker, 1993. — P. 3—11.Mazzei Т., Mini E., Novelli A., Periti P. Chemistry and mode of action of macrolides // J. Antimicrob. Chemother. — 1993. — Vol. 31, Suppl. C. — P. l—9.Mazzei Т., Mini E., Novelli A., Periti P. Chemistry and mode of action of macrolides // J. Antimicrob. Chemother. — 1993. — Vol. 31, Suppl. C. — P. l—9.Williams J.D., Sefton A.M. Comparison of macrolite antibiotics // Ibid. — P. l1—26.Williams J.D., Sefton A.M. Comparison of macrolite antibiotics // Ibid. — P. l1—26.Auckenthaler R.W., Zwahlen A., Waldvogel F.A. Macrolides // Peterson P.K., Verhoef J. The Antimicrobial Agents Annual / 1. — Amsterdam: Elsevier, 1986. — P. l15—126.Auckenthaler R.W., Zwahlen A., Waldvogel F.A. Macrolides // Peterson P.K., Verhoef J. The Antimicrobial Agents Annual / 1. — Amsterdam: Elsevier, 1986. — P. l15—126.Acar J.F., Goldstein F.W. In vitro activity against gram-positive and gram-negative bacteria // Neu H.C., Young L.S., Zinner S.H. Eds. The New Macrolides, Azalides, and Streptogramins. — New York: Marcel Dekker, 1993. — P. 13—24.Acar J.F., Goldstein F.W. In vitro activity against gram-positive and gram-negative bacteria // Neu H.C., Young L.S., Zinner S.H. Eds. The New Macrolides, Azalides, and Streptogramins. — New York: Marcel Dekker, 1993. — P. 13—24.Ridgway G.L. Current Challenges in the Global Anliinfectives. — London: London Press Centre, 1993. — P. l—21.Ridgway G.L. Current Challenges in the Global Anliinfectives. — London: London Press Centre, 1993. — P. l—21.Calia F.M. Erythromycin // Gorbach S.L., Bartlett J.G., Blacklow N.R. Eds. Infectious Diseases. — Philadelphia: Saunders, 1992. — P. 223—231.Calia F.M. Erythromycin // Gorbach S.L., Bartlett J.G., Blacklow N.R. Eds. Infectious Diseases. — Philadelphia: Saunders, 1992. — P. 223—231.Hamilton-Miller J.M.T. In-vitro activities of 14-, 15- and 16-membered macrolides against gram-positive cocci // Antimicrob. Chemother. — 1992. — Vol. 29. — P. 141—147.Hamilton-Miller J.M.T. In-vitro activities of 14-, 15- and 16-membered macrolides against gram-positive cocci // Antimicrob. Chemother. — 1992. — Vol. 29. — P. 141—147.Wiley P.F. Macrolide antibiotics // Kuemmerle H.P., Diakos G.K., Jeljaszewicz J., Spizy K.H., Umerzawa H. Eds. Clinical Chemotherapy — Antimicrobial Chemotherapy.— Stuttgart: Thieme, 1983. — P. 163—176.Wiley P.F. Macrolide antibiotics // Kuemmerle H.P., Diakos G.K., Jeljaszewicz J., Spizy K.H., Umerzawa H. Eds. Clinical Chemotherapy — Antimicrobial Chemotherapy.— Stuttgart: Thieme, 1983. — P. 163—176.McDonald P.J., Prull H. Macrolides ang the immune system // Scand. J. Infect. Dis. — 1992. — Vol. 83, Suppl. — P. 34—40.McDonald P.J., Prull H. Macrolides ang the immune system // Scand. J. Infect. Dis. — 1992. — Vol. 83, Suppl. — P. 34—40.Peters D.N., Friedei H.A., McTavish D. Azithromycin — A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy // Drugs. — 1992. — Vol. 44.— P. 750—799.Peters D.N., Friedei H.A., McTavish D. Azithromycin — A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy // Drugs. — 1992. — Vol. 44.— P. 750—799.Holliday S.M., Faulds D. Miocamycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential // Ibid. — 1993. - Vol. 46. — P. 720—745.Holliday S.M., Faulds D. Miocamycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential // Ibid. — 1993. - Vol. 46. — P. 720—745.Adam D. Clinical use of the new macrolides, azalides, and streptogramins in pediatrics // J. Chemother. — 1992. — Vol. 4. — P. 371—375.Adam D. Clinical use of the new macrolides, azalides, and streptogramins in pediatrics // J. Chemother. — 1992. — Vol. 4. — P. 371—375.Reese R.E., Betts R.F. A Practical Approach to Infectious Diseases. 3-rd Ed. — Boston: Little Brown, 1991. — P. 964—968.Reese R.E., Betts R.F. A Practical Approach to Infectious Diseases. 3-rd Ed. — Boston: Little Brown, 1991. — P. 964—968.Peeters T.L. Erythromycin and other macrolides as prokinetic agenst // Gastroenterology. — 1993. — Vol. 105. — P. 1886—1899.Peeters T.L. Erythromycin and other macrolides as prokinetic agenst // Gastroenterology. — 1993. — Vol. 105. — P. 1886—1899.Okamoto S., Haruma K., Uemura N., Sanuki E., Kawaguchi K., Inoue K., Sumii K., Kajiyama G. Study of eradication of Helicobacter pylori by the combination of roxithromycin, bismuth subnitrate, and omeprazole // Einhorn J., Nord C.E., Norrby S.R. Eds. Recent Advances in Chemotherapy. — Washihdton: American Society for Microbiology, 1993. — P. 233—233.Okamoto S., Haruma K., Uemura N., Sanuki E., Kawaguchi K., Inoue K., Sumii K., Kajiyama G. Study of eradication of Helicobacter pylori by the combination of roxithromycin, bismuth subnitrate, and omeprazole // Einhorn J., Nord C.E., Norrby S.R. Eds. Recent Advances in Chemotherapy. — Washihdton: American Society for Microbiology, 1993. — P. 233—233.Peters D.H., Clissold S.P. Clarithromycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential // Drugs. — 1992. — Vol. 44. — P. l17—164.Peters D.H., Clissold S.P. Clarithromycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential // Drugs. — 1992. — Vol. 44. — P. l17—164.Peterson W.L., Graham D.Y., Mar shall B., Blaser M.J. et al. Clarithromycin as monotherapy for eradication of Helicobacter pylory: A randomized, double-blind trial // Am. J. Gasroenterol. — 1993. — Vol. 88. — P. 1860—1864.Peterson W.L., Graham D.Y., Mar shall B., Blaser M.J. et al. Clarithromycin as monotherapy for eradication of Helicobacter pylory: A randomized, double-blind trial // Am. J. Gasroenterol. — 1993. — Vol. 88. — P. 1860—1864.Rodvold K.A., Piscitelli S.C. New oral macrolide and fluoroquinolone antibiotics. An overview of pharmacokinetics, interactions, and safety // Clin. Infect. Dis. — 1993. — Vol.17, Suppl.I. — P. S192—S199.Rodvold K.A., Piscitelli S.C. New oral macrolide and fluoroquinolone antibiotics. An overview of pharmacokinetics, interactions, and safety // Clin. Infect. Dis. — 1993. — Vol.17, Suppl.I. — P. S192—S199.Foulds G., Johnson R.B. Selection of dose regiments of azithromycin // J. Antimicrob. Chemother. — 1993. — Vol. 31, Suppl. E. — P. 39—40.Foulds G., Johnson R.B. Selection of dose regiments of azithromycin // J. Antimicrob. Chemother. — 1993. — Vol. 31, Suppl. E. — P. 39—40.Neu H.C. Clinical use in adults // Neu H. C. et al. Eds. The New Macrolides, Azalides, and Streptogramins. — New York: Marcel Dekker, 1993. — P. 85—94.Neu H.C. Clinical use in adults // Neu H. C. et al. Eds. The New Macrolides, Azalides, and Streptogramins. — New York: Marcel Dekker, 1993. — P. 85—94.

The authors declare that there are no conflicts of interest present.